Biotech News
Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AUSTIN, Texas and DURHAM, N.C., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that it has granted inducement equity awards on November 10, 2026 (the “Grant Date”) to two newly-hired non-executive employees.
